Guided View New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.
Expert View You already know the biology. Just the content, clean and compact, with no extra explanations. This is the default view.
Interface language
Light mode
Clinical trial · Inherited blindness
BRILLIANCE: the first in vivo CRISPR administration to a human organ
Official title: Single Ascending Dose Study of EDIT-101 in Participants With Leber Congenital Amaurosis Type 10
CompletedPhase I/IINCT03872479
Clinical researchBeing tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
What this trial is testing
The first time CRISPR was injected directly into a human organ: under the retina, to remove a faulty piece of a gene causing severe inherited blindness. Some participants saw meaningfully better. The programme was later discontinued because too few people in the world have that exact mutation.
An open-label, single ascending dose Phase 1/2 study of EDIT-101, delivered by subretinal AAV5 injection, in participants with CEP290-associated Leber congenital amaurosis type 10. Published results reported clinically meaningful improvement in visual function in a subset of participants with an acceptable safety profile. Editas subsequently discontinued development for population-size reasons.
What a trial result does and does not mean
Early-phase results come from small numbers of participants and short follow-up. They can change with more people and more time, and a trial that is recruiting, active or even completed has not established that a treatment works. Enrolment criteria are strict; eligibility is decided by the trial site, never by a website.
Written by CRISPR Decoded editorial teamLast updated Oct 27, 2026
Connected in CRISPR Decoded
Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.
This link opens a website we do not run. We cannot control its content, its accuracy, or how it handles your data, including its own cookies and tracking. Nothing you read there has been reviewed by us.